Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Determining the individualized probability of myocardial recovery: The multicenter RecoverHeart calculator.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026

Same author

Durable Left-Ventricular Assist Device Inflow Thrombosis Following External Outflow Graft Obstruction.

JACC. Case reports·2025

Same author

How to diagnose and manage emergency medical conditions in patients on left ventricular assist device support: A clinician's field guide.

Trends in cardiovascular medicine·2024

Same author

Using electronic medical records to identify patients at risk for underlying cardiac amyloidosis.

Journal of cardiology·2024

Same author

Reversing Advanced Heart Failure and its Practice?

JACC. Heart failure·2024

Same author

Editorial: Insights in heart failure and transplantation: 2022.

Frontiers in cardiovascular medicine·2023

Search research articles

Related Experiment Video

Updated: Jun 9, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Molecular changes occurring during reverse remodelling following left ventricular assist device support.

Emma J Birks¹, Robert S George

¹Transplantation and Mechanical Support, University of Louisville, 201 Abraham Flexner Way, Louisville, KY 40222, USA. e.birks@imperial.ac.uk

Journal of Cardiovascular Translational Research

|September 8, 2010

Summary

Left ventricular assist devices (LVADs) can reverse heart failure remodelling and improve heart function. Some patients recover enough to have the LVAD removed, leading to a normal life.

More Related Videos

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Related Experiment Videos

Last Updated: Jun 9, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Area of Science:

Cardiovascular Medicine
Biomedical Engineering

Background:

Heart failure is characterized by cardiac remodelling.
Left ventricular assist devices (LVADs) are used to support failing hearts.

Purpose of the Study:

To review molecular changes in the myocardium due to LVAD unloading.
To examine myocardial recovery and potential device explantation.

Main Methods:

Review of studies on LVAD patients.
Analysis of molecular changes in myocytes and the cardiac matrix.

Main Results:

LVAD unloading reverses adverse remodelling in advanced heart failure.
Improved myocardial function can lead to sufficient recovery for device removal.
Molecular alterations occur in both cardiac myocytes and the extracellular matrix.

Conclusions:

LVAD therapy can induce significant myocardial recovery.
Reversal of remodelling and functional improvement are key outcomes.
Complete recovery may allow for LVAD explantation in select patients.